Option Care Health, Inc. (OPCH) Stock Price & Analysis
Option Care Health, Inc. (OPCH) closed at USD 31.29 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 31.29; the Oct 22, 2026 session ranged USD 31.29–31.36 on volume of 1,933,824 shares. Market capitalization is $4.69B, with a 52-week range of USD 18.01–36.8 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OPCH.md
Key facts (OPCH)
- Last four reported quarters (through Jun 30, 2026): revenue $5.69B, net income $210M (3.7% margin), free cash flow $304M (SEC filings).
- Valuation: P/E 22.4x (avg 22.3x at the last 3 fiscal year-ends), EV/EBITDA 14.1x, net debt $965M.
- 1 of 80 tracked superinvestors hold OPCH (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market purchases, last ~7 months: 4 Form 4 filings, $1.9M; 1 by opportunistic insiders, 0 by routine insiders.
- Analysts: Hold (mean 3.00 on a 1–5 scale) (11 analysts), mean target USD 30.03 (range 23–33).
- Total return with dividends: 1Y +11.6% vs S&P 500 +14.9%; 5Y +18.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 0.49, revenue estimate $1.48B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OPCH)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.44B | $3.94B | $4.30B | $5.00B | $5.65B | $5.69B |
| Gross profit | $780M | $867M | $981M | $1.01B | $1.09B | — |
| Operating income | $191M | $240M | $315M | $322M | $338M | $334M |
| Net income | $140M | $151M | $267M | $212M | $208M | $210M |
| EPS (diluted) | $0.77 | $0.83 | $1.48 | $1.23 | $1.27 | — |
| Free cash flow | $183M | $232M | $329M | $288M | $217M | $304M |
| Gross margin | 22.7% | 22.0% | 22.8% | 20.3% | 19.3% | — |
| Operating margin | 5.5% | 6.1% | 7.3% | 6.4% | 6.0% | 5.9% |
| Net margin | 4.1% | 3.8% | 6.2% | 4.2% | 3.7% | 3.7% |
| Revenue growth | +13.4% | +14.7% | +9.1% | +16.2% | +13.0% | — |
| Cash + short-term investments | $119M | $294M | $344M | $413M | $233M | — |
| Total debt | $1.07B | $1.06B | $1.06B | $1.11B | $1.16B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (OPCH)
P/E 22.4x · P/S 0.8x · EV/EBITDA 14.1x · EV/Sales 1.0x · P/FCF 15.4x · P/B 3.7x · FCF yield 6.48% · Earnings yield 4.47% · Net debt $965M · EV $5.65B
P/E at fiscal year-ends: Dec 2025 25.1x, Dec 2024 18.9x, Dec 2023 22.8x.
Superinvestors (SEC 13F-HR, Q2 2026) (OPCH)
1 of 80 tracked investors hold OPCH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Henry Ellenbogen | Durable Capital Partners | 1.26% | $129M | Reduced -31.4% |
Insider purchases (SEC Form 4, open-market, last ~7 months) (OPCH)
4 purchases, $1.9M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-07 | Sullivan Timothy P | Director | 24,154 | $500K | 20.69 | Too little history (no open-market trades in 2023) |
| 2026-05-04 | Kraemer Harry M Jansen Jr | Director | 36,610 | $784K | 21.41 | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-04 | Sethna Meenal | Chief Financial Officer | 16,225 | $327K | 20.16 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-04 | Rademacher John Charles | Chief Executive Officer | 12,500 | $265K | 21.18 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (OPCH)
Consensus Hold (mean 3.00 on a 1–5 scale), 11 analysts; mean target USD 30.03 (low 23, high 33).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | UBS | Downgrade | Buy → Neutral | $39 → $32.05 |
| 2026-10-07 | William Blair | Downgrade | Outperform → Market Perform | |
| 2026-10-07 | JP Morgan | Downgrade | Overweight → Neutral | $33 |
| 2026-10-07 | Citizens | Downgrade | Market Outperform → Market Perform | |
| 2026-10-07 | Jefferies | Downgrade | Buy → Hold | $28 → $32.05 |
| 2026-10-07 | Barrington Research | Downgrade | Outperform → Market Perform | |
| 2026-07-30 | Deutsche Bank | Downgrade | Buy → Hold | $26 → $24 |
| 2026-07-17 | Stephens & Co. | Downgrade | Overweight → Equal-Weight | $30 → $24 |
Total return (dividends reinvested) (OPCH)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +11.6% | +18.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +11.6% | +3.4% |
| Volatility (annualized) | 52.0% | 38.8% |
| Max drawdown | -46.6% (Jan 2026→May 2026) | -46.2% (Jan 2026→May 2026) |
OPCH suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | UnitedHealth (UNH) | “The Company's competitors within the home infusion market include Optum Infusion Pharmacy (a unit of UnitedHealth Group), Coram CVS/specialty infusion services (a division of CVS Health), Amerita Specialty Pharmacy (a division of BrightSpring Health), KabaFusion, Soleo Health, Vital Care and many other regional and local home infusion companies, ambulatory infusion centers, or specialty pharmacies including Accred…” |
| Competitor | CVS Health (CVS) | “The Company's competitors within the home infusion market include Optum Infusion Pharmacy (a unit of UnitedHealth Group), Coram CVS/specialty infusion services (a division of CVS Health), Amerita Specialty Pharmacy (a division of BrightSpring Health), KabaFusion, Soleo Health, Vital Care and many other regional and local home infusion companies, ambulatory infusion centers, or specialty pharmacies including Accred…” |
Quoted from the company's 10-K filed Feb 24, 2026.
OPCH customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 14% of revenue, per the company's 10-Q filed Jul 29, 2026. The company does not name it.
OPCH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.49 | $0.48 | +1.1% | $1.48B | 11 |
| Next quarter (ends Dec 2026) | $0.54 | $0.54 | +1.5% | $1.49B | 10 |
| Current fiscal year (ends Dec 2026) | $1.88 | $1.84 | +2.2% | $5.76B | 11 |
| Next fiscal year (ends Dec 2027) | $2.08 | $2.05 | +1.6% | $6.13B | 11 |
OPCH options: expected move
Options price a move of about ±3.4% (±$1.08) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±7.2% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 11.2% | ±3.4% |
| Jan 15, 2027 | 84 | 13.0% | ±5.5% |
| Apr 16, 2027 | 175 | 12.7% | ±8.0% |
30-day implied volatility 7.8% vs 84.5% realized over the last 30 trading days. Put/call ratio (volume) 0.03. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 31.29 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 31.29 |
| Open | USD 31.33 |
| Day Range | USD 31.29 – 31.36 |
| 52-Week Range | USD 18.01 – 36.8 |
| Volume | 1,933,824 shares |
| Market Cap | $4.69B |
| Exchange | NMS |
Technical Analysis (OPCH)
Nexqual's technical model rates OPCH "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 81.73 (overbought) |
| vs SMA50 | Above (USD 25.57) |
| MACD | 1.99 (positive) |
Analyst Ratings (OPCH)
Wall Street analysts rate OPCH "Hold" based on 11 analysts, with a mean price target of USD 30.03 (range USD 23–33), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 30.03 |
| High Target | USD 33 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 0 / 11 / 0 |
Earnings (OPCH)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.49 |
| Revenue Estimate | $1.48B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.45 vs est 0.43 ▲ beat |
| 2026-03-31 | USD 0.4 vs est 0.37 ▲ beat |
| 2025-12-31 | USD 0.46 vs est 0.47 ▼ miss |
| 2025-09-30 | USD 0.45 vs est 0.43 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (OPCH)
| Total Revenue | $5.69B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1.90% |
| Gross Margin | +19.06% |
| Operating Margin | +5.90% |
| Profit Margin | +3.68% |
| ROE | +16.00% |
| Debt / Equity | 1.01 |
| Current Ratio | 1.47 |
| Total Cash | $196.78M |
| Total Debt | $1.27B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $303.85M (5.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (OPCH)
Nexqual rates Option Care Health, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Solid — Revenue +13% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 19%, operating 6% (last 12 months) |
| Balance Sheet | Mixed — $194M cash and investments vs $1.16B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $304M (last 4 quarters to Jun 2026, SEC), 5% margin |
| Efficiency | Solid — ROE 16%, ROA 6.2% |
Ownership (OPCH)
| Insider Ownership | +1.28% |
|---|---|
| Institutional Ownership | +109.02% |
| Shares Outstanding | 149.79M |
| Float | 147.71M |
| Short % of Float | +7.97% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (OPCH)
Option Care Health, Inc. is led by John Charles Rademacher, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.
| CEO, President & Director | John Charles Rademacher |
|---|---|
| Executive VP & CFO | Meenal Anil Sethna C.P.A. |
| Chief Operating Officer | Luke Whitworth |
| Chief Technology Officer | Brett Michalak |
Major Backers & Investors (OPCH)
Notable institutional backers of Option Care Health, Inc. include Wellington Management, Fuller & Thaler Asset Management Inc., Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 7.87% |
| Fuller & Thaler Asset Management Inc. | 4.97% |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 4.78% |
| Durable Capital Partners Lp | 4.12% |
| Arrowstreet Capital, Limited Partnership | 3.99% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 14.76% |
| Vanguard Group | 10.24% |
| State Street | 4.1% |
| Dimensional Fund Advisors | 3.64% |
| Geode Capital | 2.98% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Option Care Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Partnerships
- Any person or entity participating in a circumvention scheme to avoid the referral prohibitions is liable for CMPs, and additional fines may be imposed for failure to comply with reporting requirements regarding an entity's ownership, investment and compensation arrangements for each day for which reporting is required to have been made under the Stark Law.
Legal & Regulatory Risks (Item 1A, quoted)
- Regulatory changes, increased scrutiny, or reclassification of our compounding practices as an FDA-regulated outsourcing facility could lead to costly compliance requirements, operational disruptions, and reputational harm.
- Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us.
- We may be subject to liability claims for damages and other expenses that are not covered by insurance.
- The development and use of AI technologies could expose us to significant governance, compliance, and legal liabilities, including evolving regulatory requirements, heightened scrutiny, litigation risk, and substantial compliance costs, that may adversely affect our operations, financial condition, and ability to successfully adopt and deploy AI.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LFST | LifeStance Health Group, Inc. | USD 12.56 | ▲ 1.87% |
| CON | Concentra Group Holdings Parent | USD 39.97 | ▲ 2.25% |
| NHC | National HealthCare Corporation | USD 243.07 | ▲ 3.17% |
| CHE | Chemed Corp | USD 520.15 | ▲ 1.72% |
| ACHC | Acadia Healthcare Company, Inc. | USD 31.88 | ▲ 1.43% |
| PACS | PACS Group, Inc. | USD 47.5 | ▲ 1.58% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt